RxDoctor Payments Data

Neha Agarwal, MD

Internal Medicine · Los Angeles, CANPI 1013379551

Payments from drug & device makers

$1,071in general payments, 2019–2025

Across 27 payments — averaging $39.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$176
  • GSK$175
  • AstraZeneca$152
  • Edwards Lifesciences$130
  • Boehringer Ingelheim$126
  • Genentech USA, Inc.$100
  • plus $212 from 7 others

What the payments were for

  • Food & beverage$97191%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,071 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$132,730
Medicare patients
354
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide52$30,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,043
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$13,328
EliquisApixaban15$13,321
Breo ElliptaFluticasone/Vilanterol13$9,425
Incruse ElliptaUmeclidinium Bromide18$7,469
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,013
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$4,119
SymbicortBudesonide/Formoterol Fumarate11$3,107
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,084
BreynaBudesonide/Formoterol Fumarate12$2,826
Arnuity ElliptaFluticasone Furoate13$2,744
Albuterol Sulfate HfaAlbuterol Sulfate77$2,276
Wixela InhubFluticasone Propion/Salmeterol14$1,066
Montelukast Sodium26$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$175$52,00998 claims
Boehringer IngelheimSpiriva Respimat$126$30,86052 claims
PfizerEliquis$70$13,32115 claims
AstraZenecaBreztri Aerosphere, Symbicort$152$9,12022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →